Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFX-1 in moderate to severe Hidradenitis Suppurativa
NCT03001622Phase 2Completed
- Sponsor
- InflaRx
- Start
- Dec 2016
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vilobelimab in hidradenitis suppurativa (HS), sponsored by InflaRx. Started Dec 2016; status: completed.
02
Drugs
vilobelimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03001622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001622.